Age as a modifiable risk factor for cardiovascular disease (Q37102653)

18 August 2017

1 reference

title

Age as a modifiable risk factor for cardiovascular disease (English)

1 reference

18 August 2017

0 references

cardiovascular disease

1 reference

1

Allan D Sniderman

1 reference

18 August 2017

Curt D Furberg

2

1 reference

PubMed ID

18321568

18 August 2017

language of work or name

English

0 references

publication date

5 March 2008

1 reference

18 August 2017

1 reference

18 August 2017

371

1 reference

18 August 2017

9623

1 reference

18 August 2017

1547-1549

1 reference

Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation.

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

The limitations of risk factors as prognostic tools

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

Comparison of apolipoprotein B and non-high-density lipoprotein cholesterol for identifying coronary artery disease risk based on receiver operating curve analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

Multiple biomarkers for the prediction of first major cardiovascular events and death

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

The effect of including C-reactive protein in cardiovascular risk prediction models for women.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

Relation of age, the apolipoprotein B/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

Framingham risk score and prediction of lifetime risk for coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

Blood pressure and ageing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

CORONARY DISEASE AMONG UNITED STATES SOLDIERS KILLED IN ACTION IN KOREA

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

Early adult risk factor levels and subsequent coronary artery calcification: the CARDIA Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960313-X

7 January 2021

10.1016/S0140-6736(08)60313-X

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18321568